Sun, Sep 14, 2014, 11:13 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

Dooper55 9 posts  |  Last Activity: Aug 12, 2014 9:39 AM Member since: Dec 9, 2006
  • Ah the joys of financial reporting. Yesterday's Q2 reports said OMER missed estimates by 7¢/sh ...... BUT, just getting corrected ..... they beat estimates by 4¢/sh

  • Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference

    SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference in New York next week. The presentation is scheduled for Tuesday, August 12 at 12:45pm EDT.

    The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website.

  • Omeros Corporation Reports Second Quarter 2014 Financial Results
    Mon August 11, 2014 4:03 PM|PR Newswire | About: OMER
    SEATTLE, Aug. 11, 2014 /PRNewswire/ -- Omeros Corporation (OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014, which include:

    2Q 2014 net loss of $18.0 million, or $0.53 per share, which included $2.5 million ($0.07 per share) of non-cash expenses
    Operating expenses of $17.3 million, primarily related to preparing for U.S. commercial launch of Omidria" and advancing OMS824 and OMS721 clinical programs
    U.S. Food and Drug Administration (FDA) approval of Omidria" (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain
    FDA clearance of Investigational New Drug (IND) application for Phase 2 clinical trial evaluating OMS721 in thrombotic microangiopathies (TMAs) and initiated Phase 2 trial
    "Obtaining U.S. marketing approval for Omidria is a tremendous accomplishment for Omeros," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "It marks a pivotal point in our transition to a commercial company, and we are continuing preparations for a planned U.S. product launch in the fourth quarter of 2014. In that same time frame, we also expect to receive a decision on the EU marketing application for Omidria. While we remain focused on the market launch of Omidria, we continue to advance the rest of our pipeline, including our MASP-2 inhibitor OMS721 and PDE10 inhibitor OMS824 Phase 2 clinical programs in patients with TMAs and Huntington's.

  • OMER's short interest dropped just over 150,000 shares during the second half of June.

    6/13/2014 ......... 5,978,036

    6/30/2014 ......... 5,823,043

    Apparently the 2.5+ million share volume surge on June 23, 24 and 25, when the share price rose from $14.35 to $17.47, was accumulation, not short covering.

  • dooper55 dooper55 Jul 3, 2014 8:10 AM Flag

    scubamoe, I expect to see continued price increases because I generally agree with the logic (if not the price targets) of analysts like WBB and Wedbush that have price targets WAY north of where OMER is today.

    Omidria is approved and their pipeline is fascinating. It'll be interesting to see what's happening with the huge short position that was still about 6 million shares mid-June. 2.5 million shares traded in three days early last week while the stock went from $14.50 to $17.50. That could have been substantial short covering but it'd still leave a big short position.

  • dooper55 dooper55 Jul 2, 2014 12:24 PM Flag

    Peter (not Gregory) Demopulos, a BoD member, bought those shares. Still a good sign.

  • Today (Friday), EADO event, Munich:

    08:00 - 10:00 SYMPOSIUM IV

    New drugs and trials: An update on immunotherapy and chemotherapy

    09:24 - 09:34 PV-10 Vernon Sondak, Tampa, USA [That'd be Moffitt]

    Topics in the session, in sequence:

    Ipilimumab, Nivolumab, MK3475, Biomarkers for PD-1 response, IL19, MAGE-A3 ASCI, T_VEC, PV-10, Electroporation, Nab-paclitaxel

  • How do you spell squeeeeeeeeeeeze?

  • Google that subject to see the whole article.

    "Moffitt will receive the largest share of the initial $60 million, about $26 million. It will use the money to hire more researchers, particularly in the field of immunology, harnessing the immune system to help patients fight cancer."

14.45-0.16(-1.10%)Sep 12 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
21Vianet Group, Inc.
NasdaqGSFri, Sep 12, 2014 4:00 PM EDT
Darden Restaurants, Inc.
NYSEFri, Sep 12, 2014 4:03 PM EDT